Family Medicine

As we begin our annual health care recap series this month, let's take a look back at the stories our readers liked most.

Despite its frequent use as a rescue therapy for patients with interstitial lung disease associated with connective tissue disorder, the effectiveness of rituximab hasn't been evaluated in many clinical trials.

Investigators aimed to characterize and evaluate the prevalence of sleep symptoms in patients with long COVID syndrome.

Factors including trust of information, fear, and resilience were related to insomnia and suicidal thoughts in healthcare workers, general population and outpatients.

The burden of sleep disorders is high among the transgender or gender-nonconforming population and this study evaluated the role of gender-affirming therapy on that relationship.

Post hoc analysis data from JADE REGIMEN show continuous and reduced-dose regimens provided similar efficacy and safety outcomes in the 2 age groups.

Phase 3 data suggest children aged <6 months to 5 years old have benefit in itch relief and skin clearance as soon as 1 week into systemic therapy regimens.

Sleep Medicine Expert Daniel Gottlieb, MD, MPH, details a response to the USPSTF screening recommendations for obstructive sleep apnea in a primary care setting.

US Prevention Services Task Force (USPSTF) announces that after reviewing the clinical utility of obstructive sleep apnea screening tools in a primary care setting, there's insufficient evidence to determine the balance between benefit and harm.

"Having the ability to enhance the sleep quality in a way that is scientifically important, and also taking into account objective measurements opens a lot of possibilities," Gary Garcia-Molina, PhD, said in an interview.

Because unhealthy sleep is associated with multiple conditions and higher risk of mortality, investigators call for further research on the potential to optimize overall sleep health in the US.

Gary Garcia-Molina, PhD, explains precisely how Sleep Number smart bed technology works after conducting multiple sleep studies.

Nonprofit organizations combined efforts to plan a meeting to inform and educate the FDA and key stakeholders about the experience of caregivers and patients with Phelan-McDermid syndrome (PMS).

Investigators evaluated how the risk of kidney failure and death affects US veterans with chronic kidney disease (CKD) in research presented at Kidney Week 2022 ASN Annual Meeting.

New research presented at Kidney Week 2022 ASN Annual Meeting, demonstrates an association between albuminuria and risk of cognitive problems.

New data from the International Pediatric Sleep Association (IPSA) Congress 2022 used smart bed technology that revealed consistent findings to previous studies.

Evaluating the stigma associated with various dermatologic conditions is more accessible with the validated PUSH-D questionnaire.

Dr. Neera Dahl explains that patients with autosomal dominant polycystic kidney disease (ADPKD) are often referred to a nephrologist when imaging is done for another concern.

Depressive disorders are often accompanied by low levels of resilience and research indicates that targeting insomnia symptoms could address the severity of these psychiatric disorders.

Investigators are urging for more research on the mechanisms involved with comorbid insomnia and obstructive sleep apnea (OSA) to reduce the mortality risk in patients with both sleep disorders.

Iptacopan has the potential to address an unmet need in PNH by significantly increasing hemoglobin levels in patients who remain anemic, fatigued and dependent on blood transfusions after anti-C5 treatment.

A highlighted description of some key takeaways from presentations at Pri-Med Midwest 2022, including such topics as infectious disease, monkeypox, colorectal cancer, psoriasis, and COVID-19.

Catherine Nester, RN, and Dr. Stephen Kingsmore, discuss the pivotal role of newborn screening in diagnosing rare diseases along with the impact that BeginNGS can have on the future of rare disease medicine.

"Especially when untreated and in late stages of progression, ILD is well known to impact health related quality of life," according to Dr. Briana DiSilvio. "Chronic dyspnea, cough, and reduced exercise capacity can become disabling."

Various consequences have been linked to nightmares and can have a severe impact on mental health, even leading to increased risk of suicide.